1. Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:1561-73

2. Baseline Demographic Characteristics and Medications at the Time of Randomization Nissen SE, et al. JAMA 2008;299:1561-73

3. Baseline and On-Treatment Vital Signs and Laboratory Values in Participants Completing the Trial (n=360) a Nissen SE, et al. JAMA 2008;299:1561-73

4. Changes in Mean Hemoglobin A1c, Fasting Plasma Glucose Levels, High-Density Lipoprotein Cholesterol, and C-Reactive Protein During the Trial (n = 360) Nissen SE, et al. JAMA 2008;299:1561-73

5. Baseline, Follow-up, and Change From Baseline in Intravascular Ultrasound End Points Nissen SE, et al. JAMA 2008;299:1561-73

6. Primary Efficacy Parameter (Percent Atheroma Volume) in Prespecified Subgroups Nissen SE, et al. JAMA 2008;299:1561-73

7. Change From Baseline in Intravascular Ultrasound End Points Using Imputed Values for Noncompleters Nissen SE, et al. JAMA 2008;299:1561-73

8. Clinical End Points, Adverse Events, Laboratory Abnormalities, and Reasons for Discontinuing Participation (Safety Population, n = 543) Nissen SE, et al. JAMA 2008;299:1561-73